Published in Bone Marrow Transplant on December 01, 1993
Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol (1996) 0.86
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol (2012) 0.83
Multiple myeloma: current treatment. Postgrad Med J (1994) 0.75
The molecular genetics of hematologic malignancies. Clin Diagn Lab Immunol (1995) 0.75
The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates. Br J Cancer (1995) 0.75
A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature (1996) 27.61
Mechanisms of evolution in Rickettsia conorii and R. prowazekii. Science (2001) 5.32
Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet (1999) 4.74
Simple, rapid method for assay of aminoglycoside antibiotics. Lancet (1971) 3.35
The complete genome sequence of the murine respiratory pathogen Mycoplasma pulmonis. Nucleic Acids Res (2001) 2.75
A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family. Nat Genet (1997) 2.68
Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet (2000) 2.40
Mental calculation in a prodigy is sustained by right prefrontal and medial temporal areas. Nat Neurosci (2001) 1.70
Clustering of mutations responsible for branchio-oto-renal (BOR) syndrome in the eyes absent homologous region (eyaHR) of EYA1. Hum Mol Genet (1997) 1.59
Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet (2000) 1.58
Intraoperative ventricular puncture. Neurosurgery (1988) 1.51
CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant (1997) 1.48
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol (1997) 1.48
Arteriovenous malformations of the brain: choosing embolic materials to enhance safety and ease of excision. J Neurosurg (1992) 1.47
Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol (1994) 1.43
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood (1995) 1.43
Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD) Bone Marrow Transplant (1999) 1.42
Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet (1992) 1.40
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR. J Clin Microbiol (2009) 1.32
Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology (1975) 1.30
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
A combined frontotemporal and lateral infratemporal fossa approach to the skull base. J Neurosurg (1988) 1.24
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet (1993) 1.24
Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol (1995) 1.22
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br J Haematol (2000) 1.21
Wound-healing technologies: low-level laser and vacuum-assisted closure. Evid Rep Technol Assess (Summ) (2004) 1.21
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant (2006) 1.14
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol (1999) 1.13
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant (2006) 1.12
Intraoperative aneurysmal rupture: incidence, outcome, and suggestions for surgical management. Neurosurgery (1986) 1.11
Cutaneous reactions in relation to the use of 'TED'-stockings. Lancet (1989) 1.10
Comparison of EDTA and EDDS as potential soil amendments for enhanced phytoextraction of heavy metals. Chemosphere (2005) 1.10
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol (1989) 1.08
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev (2000) 1.07
The future of aneurysm surgery. Surg Neurol (1998) 1.07
A fluorimetric method for the measurement of pyridoxal and pyridoxal phosphate in human plasma and leucocytes, and its application to patients with sideroblastic marrows. J Clin Pathol (1983) 1.07
Aneurysm retreatment after Guglielmi detachable coil and nondetachable coil embolization: report of nine cases and review of the literature. Neurosurgery (1999) 1.06
Management of hemorrhagic complications from preoperative embolization of arteriovenous malformations. J Neurosurg (1991) 1.05
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol (2003) 1.05
Posteroinferior cerebellar artery aneurysms: surgical results for 38 patients. Neurosurgery (1998) 1.04
Role of ineffective erythropoiesis in the anaemia of rheumatoid arthritis. Ann Rheum Dis (1977) 1.03
Intracranial arteriovenous malformations associated with aneurysms. Neurosurgery (1986) 1.03
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia (2009) 1.01
Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant (1992) 1.01
Reversal of ineffective erythropoiesis in pernicious anaemia following vitamin B12 therapy. Br J Haematol (1977) 0.99
Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol (1995) 0.99
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms. Br J Rheumatol (1988) 0.98
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant (2005) 0.98
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia (2006) 0.98
Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother (1995) 0.97
Does electrothrombosis occur immediately after embolization of an aneurysm with Guglielmi detachable coils? AJNR Am J Neuroradiol (1997) 0.97
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. Leukemia (2005) 0.97
Arteriovenous malformations of the posterior fossa: clinical presentation, diagnostic evaluation and surgical treatment. Neurosurg Rev (1986) 0.97
Arteriovenous malformations of the posterior fossa. Clinical presentation, diagnostic evaluation, and surgical treatment. J Neurosurg (1986) 0.96
Preoperative embolization of cerebral arteriovenous malformations with polyvinyl alcohol particles: experience in 51 adults. AJNR Am J Neuroradiol (1990) 0.95
Quantitation of ineffective erythropoiesis from the incorporation of [15N] delta-aminolaevulinic acid and [15N] glycin into early labelled bilirubin. II. Anaemic patients. Br J Haematol (1976) 0.95
Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis (1995) 0.95
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant (2011) 0.94
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol (2004) 0.94
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant (2003) 0.94
Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia (1995) 0.93
Retrograde crossing stent placement strategies at the basilar apex for the treatment of wide necked aneurysms: reconstructive and deconstructive opportunities. J Neurointerv Surg (2009) 0.93
Nuclear requirement of post-maturational cortical differentiation of amphibian oocytes: effects of cycloheximide. J Exp Zool (1979) 0.92
Cerebral revascularization for transient ischemic attacks. Neurology (1977) 0.92
Preoperative embolization of cerebral arteriovenous malformations with onyx. AJNR Am J Neuroradiol (2008) 0.92
Quantitation of ineffective erythropoiesis from the incorporation of [15N] delta-aminolaevulinic acid and [15N] glycine into early labelled bilirubin. I. Normal subjects. Br J Haematol (1976) 0.91
Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol (1998) 0.89
Budd-Chiari syndrome in association with polycystic disease of the liver and kidneys. J R Soc Med (1992) 0.89
The anaemia of chronic disorders. Postgrad Med J (1983) 0.89
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant (2001) 0.89
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol (1997) 0.89
Surgical approaches to trigonal arteriovenous malformations. J Neurosurg (1987) 0.88
Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant (2007) 0.88
Intraarterial papaverine for relief of catheter-induced intracranial vasospasm. AJR Am J Roentgenol (1992) 0.88
Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma (1994) 0.88
Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer (1994) 0.88
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia (2004) 0.86
Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia. Clin Lab Haematol (1990) 0.86
Management of planned pregnancy in a patient with congenital antithrombin III deficiency. Br J Haematol (1984) 0.86
Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant (1995) 0.86
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy (2001) 0.86
A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. Br J Haematol (1998) 0.85
Intravascular use of isobutyl 2-cyanoacrylate: Part 2 Treatment of carotid-cavernous fistulas. Neurosurgery (1981) 0.85
Unruptured cerebral aneurysms presenting as recurrent transient neurologic deficits. Neurology (1980) 0.85
Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol (1979) 0.85